Marengo Therapeutics, Inc.
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Gene Therapy, Cell Therapy
- Large Molecule
- Pharmaceuticals
Latest on Marengo Therapeutics, Inc.
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C
Ipsen SA appears to have reset the market for US Food and Drug Administration priority review vouchers after selling its voucher to an unnamed company for $158m. Ipsen received the voucher, which can
Ipsen SA has shown itself to be a canny dealmaker over the past few years and its negotiating skills have been shown again with the sale of a priority review voucher (PRV) at well above market rate.
Ipsen SA is showing no sign of slowing down on the dealmaking front and has bagged the ex-US licensing rights to Day One Biopharmaceuticals, LLC 's recently approved brain cancer drug, Ojemda. The F